Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Outlines
Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran
Seyed Moayed Alavian1,*, Kamran B Lankarani2, Seyed Hossein Aalaei-Andabili1, Ali Pouryasin3, Nasser Daryani4, Mohsen Nasiritoosi4, Reza Malekzadeh5, Mohammad Reza Zali6, Mino Mohraz7Abstract
Complete name and affiliation of collaborators are listed at the end of this article as an Appendix ( page: 711 ).
Hepatitis C remains as an important health problem worldwide. Hepatitis C treatment, especially among patients infected with HCV genotype 1 who are considered difficult to treat, is a high priority for health policy-makers. PegInterferon alfa instead of Interferon and ribavirin combination therapy has been accepted as the standard treatment regimen for hepatitis C patients; however, only 50% of patients infected with HCV genotype 1 achieve a sustained virological response. Published data from various clinical trials of protease inhibitors suggest that new therapeutic regimens may increase the chances of a successful response in patients infected with HCV genotype 1. Triple therapy that includes boceprevir has been shown to result in high rates of sustained virological response in both naive and experienced patients with HCV genotype 1 infection. In this review, we have summarized the results obtained with this new regimen and have attempted to provide a guideline for the treatment of patients in Iran, with emphasis on cost and the occurrence of adverse events.
Implication for health policy/practice/research/medical education:
Proper treatment of hepatitis C to control the burden of disease is essential in the society. Nowadays with the new methods of therapy the hope of eradication is more than before. This study is recommended to internal medicine and infectious disease specialists, gastroenterologists, general practitioners, virologists and health policy makers.
Please cite this paper as:
Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of Chronic Hepatitis C Infection: Updated of the Recommendations from Scientific Leaders' Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011; 11(9):703-13. DOI: 10.5812/kowsar.1735143X.769
References
- 1.The references are available in the PDF file.
Copyright
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran
Alavian SM, Jabbari H, Ebrahimi Daryani N, Torabi Nami M. Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran. Hepat Mon. 2012;12(7):. doi: https://doi.org/10.5812/hepatmon.6679
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline
Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16(8):e40959. doi: https://doi.org/10.5812/hepatmon.guideline
Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017
Alavian SM, Sharafi H. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. Hepat Mon. 2017;17(11):e63956. doi: https://doi.org/10.5812/hepatmon.63956
Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013
Ebrahimi Daryani N, Alavian SM, Somi MH, Torabi-Nami M. Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013. Hepat Mon. 2013;13(11):e16082. doi: https://doi.org/10.5812/hepatmon.16082
Epidemiology of Hepatitis C in Iran and the World.
Alavian S, Fallahian F. Epidemiology of Hepatitis C in Iran and the World.. Shiraz E-Med J. 2009;10(4):. doi:
- Scopus by DOI: 0
Last Update: 2 weeks ago
- Scopus by Title: 0
Last Update: 2 weeks ago
- Scopus by Title (Ref): 7
Last Update: 2 weeks ago
- CrossRef: 0
Last Update: 4 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC
Author(s):
- Seyed Moayed Alavian:[PubMed][Scholar]
- Kamran B Lankarani:[PubMed][Scholar]
- Seyed Hossein Aalaei-Andabili:[PubMed][Scholar]
- Ali Pouryasin:[PubMed][Scholar]
- Nasser Daryani:[PubMed][Scholar]
- Mohsen Nasiritoosi:[PubMed][Scholar]
- Reza Malekzadeh:[PubMed][Scholar]
- Mohammad Reza Zali:[PubMed][Scholar]
- Mino Mohraz:[PubMed][Scholar]